Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles.
OBJECTIVE
The study reports the initial biological evaluation of targeted polymeric glycol chitosan vesicles as carrier systems for doxorubicin (Dox).


METHODS
Transferrin (Tf) was covalently bound to the Dox-loaded palmitoylated glycol chitosan (GCP) vesicles using dimethylsuberimidate (DMSI). For comparison, glucose targeted niosomes were prepared using N-palmitoyl glucosamine. Biological properties were studied using confocal microscopy, flow cytometry, and cytotoxicity assays as well as a mouse xenograft model.


RESULTS
Tf vesicles were taken up rapidly with a plateau after 1-2 h and Dox reached the nucleus after 60-90 min. Uptake was not increased with the use of glucose ligands, but higher uptake and increased cytotoxicity were observed for Tf targeted as compared to GCP Dox alone. In the drug-resistant A2780AD cells and in A431 cells, the relative increase in activity was significantly higher for the Tf-GCP vesicles than would have been expected from the uptake studies. All vesicle formulations had a superior in vivo safety profile compared to the free drug.


CONCLUSIONS
The in vitro advantage of targeted Tf vesicles did not translate into a therapeutic advantage in vivo. All vesicles reduced tumor size on day 2 but were overall less active than the free drug.
Laboratoire de Biologie des Interactions Cellulaires, CNRS UMR 6558, Faculté des Sciences, Poitiers, France.
Christine
C
Dufes
Jean-Marc
JM
Muller
William
W
Couet
Jean-Christophe
JC
Olivier
Ijeoma F
IF
Uchegbu
Andreas G
AG
Schätzlein
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D045744:Cell Line, Tumor; D002686:Chitin / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D048271:Chitosan; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity; D004337:Drug Carriers / Q000008:administration & dosage / Q000493:pharmacokinetics; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007275:Injections, Intravenous; D051379:Mice; D008819:Mice, Nude; D011108:Polymers / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014168:Transferrin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D023041:Xenograft Model Antitumor Assays / Q000379:methods
D000970:Antineoplastic Agents; D004337:Drug Carriers; D011108:Polymers; D014168:Transferrin; D002686:Chitin; D004317:Doxorubicin; D048271:Chitosan